Rivernorth Capital Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Rivernorth Capital Management’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-99,996	Closed	-$1M	–	797
2022 Q3	$1M	Hold	99,996	–	–	0.05%	371
2022 Q2	$990K	Hold	99,996	–	–	0.04%	370
2022 Q1	$986K	Hold	99,996	–	–	0.04%	383
2021 Q4	$976K	Hold	99,996	–	–	0.04%	334
2021 Q3	$978K	Hold	99,996	–	–	0.05%	265
2021 Q2	$985K	Hold	99,996	–	–	0.06%	234
2021 Q1	$998K	Buy	+99,996	New	+$1.03M	0.06%	200

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Rivernorth Capital Management's EUCR Position: Q4 2022 in Review

Rivernorth Capital Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 99,996 shares — an estimated $1M sold.

Rivernorth Capital Management first reported a position in EUCR in Q1 2021 and held it in 7 quarters. The position peaked at $1M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Rivernorth Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Rivernorth Capital Management sold 99,996 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $1M.
Rivernorth Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2021 and held it in 7 quarters.
Rivernorth Capital Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $1M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Rivernorth Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.